A Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Anti-Cancer Activity of Trametinib in Combination With Palbociclib in Subjects With Solid Tumors

• ClinicalTrials.gov Identifier: NCT02065063
• Recruitment Status: Completed
• First Posted: February 17, 2014
• Last Update Posted: June 1, 2018
• Sponsor: GlaxoSmithKline
• Collaborator: Pfizer
• Information provided by (Responsible Party): GlaxoSmithKline

Study Description

Brief Summary:

This is a dose-escalation, Phase I/II, open-label, three-part study. Part 1 is designed to determine the recommended dose and schedule for the orally administered MEK inhibitor trametinib, given together with the CDK4/6 inhibitor palbociclib in subjects with solid tumors. Multiple dose levels of each inhibitor will be tested to determine the recommended dose and schedule. Part 2 will evaluate the effect of the combination on tumor biomarkers safety, and anti-cancer activity in subjects with cutaneous melanoma that do not have a change at BRAFV600. Approximately 100-200 subjects will be enrolled. All subjects will receive trametinib and/or palbociclib until disease progression, death, consent withdrawal or unacceptable adverse event (AE).

Data was only collected and analyzed for the Phase I component of the study, the Phase II component of the study was terminated without data collection

Condition or disease	Intervention/treatment	Phase
Cancer	Drug: Trametinib; Drug: Palbociclib	Phase 1

Study Design

• Study Type: Interventional (Clinical Trial)
• Actual Enrollment: 28 participants
• Allocation: Non-Randomized
• Intervention Model: Crossover Assignment
• Masking: None (Open Label)
• Primary Purpose: Treatment
• Official Title: A Dose-Escalation, Phase I/II, Open-Label, Three-Part Study of the MEK Inhibitor, Trametinib, Combined With the CDK4/6 Inhibitor, Palbociclib, To Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Anti-Cancer Activity in Subjects With Solid Tumors
• Actual Study Start Date: April 22, 2014
• Actual Primary Completion Date: June 23, 2016
• Actual Study Completion Date: June 23, 2016

Arms and Interventions

Arm	Intervention/treatment
Experimental: Part 1; Part 1 is a dose finding phase in which subjects will be initially administered 75 milligram (mg) of palbociclib (21 days on/7 days off) and 1.5 mg of trametinib (once daily continuous dosing) in each 28-day cycle. Dose escalations will continue based on predefined parameters until the RCR is identified. The RCR will not exceed the maximum tolerated dose (MTD).	Drug: Trametinib; Trametinib is available as a 0.5 mg yellow oval tablet or as a 2.0 mg pink round tablet.; Drug: Palbociclib; Palbociclib is available as a 75 mg (size 2 sunset yellow) or 100 mg (size 1 sunset yellow/caramel) or 125 mg (size 0 caramel) capsule.
Experimental: Part 2; Once the MTD and schedule have been determined, two expansion cohorts of up to 20 subjects each will be enrolled. The cohorts will enroll subjects with BRAF-WT (wild type) cutaneous melanoma that are either NRAS-WT or NRAS-MUT (mutated). Subjects will be dosed at or below the RCR to determine the inhibition of selected tumor biomarkers at each dose level.	Drug: Trametinib; Trametinib is available as a 0.5 mg yellow oval tablet or as a 2.0 mg pink round tablet.; Drug: Palbociclib; Palbociclib is available as a 75 mg (size 2 sunset yellow) or 100 mg (size 1 sunset yellow/caramel) or 125 mg (size 0 caramel) capsule.
Experimental: Part 3; Part 3 will be a randomized Phase II study in which subjects will be administered the RCR as previously identified. Part 3 will be initiated only if an RCR is identified, and sufficient anticancer activity is observed in Parts 1 and 2.	Drug: Trametinib; Trametinib is available as a 0.5 mg yellow oval tablet or as a 2.0 mg pink round tablet.; Drug: Palbociclib; Palbociclib is available as a 75 mg (size 2 sunset yellow) or 100 mg (size 1 sunset yellow/caramel) or 125 mg (size 0 caramel) capsule.

Outcome Measures

Primary Outcome Measures :

1. Part 1: Change from baseline in vital signs [ Time Frame: Up to 36 months ]
   Vital sign measurements will include systolic and diastolic blood pressure, temperature, respiration rate and pulse rate
2. Part 1: Change from baseline in physical examination findings [ Time Frame: Up to 36 months ]
   A complete physical examination will include assessments of the head, eyes, ears, nose, throat, skin, thyroid, neurological, lungs, cardiovascular, abdomen (liver and spleen), lymph nodes and extremities
3. Part 1: Change from baseline in 12-lead electrocardiograms (ECG) assessment [ Time Frame: Up to 36 months ]
4. Part 1: Change from baseline in echocardiogram (ECHO) or Multi Gated Acquisition (MUGA) scans assessment [ Time Frame: Up to 36 months ]
   An ECHO (preferred) or a MUGA scan will be performed at baseline to assess cardiac ejection fraction and cardiac valve morphology for the purpose of study eligibility
5. Part 1: Change from baseline in chemistry and hematology laboratory values [ Time Frame: Up to 36 months ]
6. Part 1: Number of subjects with adverse events (AEs) [ Time Frame: From the time the first dose of study treatment is administered until 30 days following discontinuation of study treatment ]
   All subjects (approximately 50)
7. Part 1: Composite of pharmacokinetic (PK) parameters following trametinib and palbociclib administration [ Time Frame: Cycle 1 Day 15 (pre-dose, and 1, 2, 4, 6, 8, and 10 hours post dose) and Cycle 2 Day 15 (pre-dose) ]
   PK parameters will include: maximum observed plasma concentration (Cmax), time to Cmax (tmax), area under the plasma concentration-time curve (AUC[0-t]), oral clearance (CL/F), minimum observed concentration (Cmin). Blood samples of approximately 2 mL for trametinib and 2 mL for palbociclib (4 mL total) will be collected for PK analysis at each timepoint shown for all subjects (approximately 50)
8. Part 1: Number of subjects with anti-cancer activity [ Time Frame: Up to 36 months ]
   Disease progression and response evaluations will be determined according to the definitions established in the Response Evaluation Criteria in Solid Tumors (RECIST Version 1.1) for all subjects (approximately 50 in Part 1)
9. Part 2: Change from baseline in tumor biomarkers [ Time Frame: Screening and Cycle 1 Day 15 (pre-dose) ]
   Change from baseline in biomarkers like pERK, total Rb, Ki67, FoxM1, p16, and CCDN1 will be calculated. These markers will be evaluated in formalin-fixed, paraffin-embedded tissue via immunohistochemistry (IHC)

Secondary Outcome Measures :

1. Part 1: GSK1120212 and PD-0332991 PK parameters following repeat-dose administration of trametinib and palbociclib [ Time Frame: Cycle 1 Day 15 (pre-dose, and 1, 2, 4, 6, 8, and 10 hours post dose) and Cycle 2 Day 15 (pre-dose) ]
   The following PK parameters will be calculated: Area under the concentration-time curve over the dosing interval (AUC[0-tau]), minimum observed concentration (Cmin), pre-dose (trough) concentration at the end of the dosing interval (Ctau), maximum observed concentration (Cmax), time of occurrence of Cmax (tmax), and terminal phase half-life (t1/2) (if data permits)
2. Part 1 and Part 2: Number of subjects with response rate [ Time Frame: Up to 36 months for part 1 and 24 months for part 2 ]
   Subjects whose disease responds (either complete response [CR] or partial response [PR]), using RECIST Version 1.1 (up to approximately 100 subjects)
3. Part 1 and Part 2 : Number of subjects with Duration of response (DOR) [ Time Frame: Up to 36 months for part 1 and 24 months for part 2 ]
   up to approximately 100 subjects
4. Part 1 and Part 2: Number of subjects with Progression-free survival (PFS) [ Time Frame: Up to 36 months for part 1 and 24 months for part 2 ]
   up to approximately 100 subjects
5. Part 2 : Change from baseline in vital signs [ Time Frame: Up to 24 months ]
   Vital sign measurements will include systolic and diastolic blood pressure, temperature, respiration rate and pulse rate
6. Part 2: Change from baseline in physical examination findings [ Time Frame: Up to 24 months ]
   A complete physical examination will include assessments of the head, eyes, ears, nose, throat, skin, thyroid, neurological, lungs, cardiovascular, abdomen (liver and spleen), lymph nodes and extremities
7. Part 2: Change from baseline in 12-lead electrocardiograms (ECG) assessment [ Time Frame: Up to 24 months ]
8. Part 2: Change from baseline in echocardiogram (ECHO) or Multi Gated Acquisition (MUGA) scans assessment [ Time Frame: Up to 24 months ]
   An ECHO (preferred) or a MUGA scan will be performed at baseline to assess cardiac ejection fraction and cardiac valve morphology for the purpose of study eligibility
9. Part 2 : Change from baseline in chemistry and hematology laboratory values [ Time Frame: Up to 24 months ]
10. Part 2 : Number of subjects with adverse events (AEs) [ Time Frame: From the time the first dose of study treatment is administered until 30 days following discontinuation of study treatment ]
    up to 40 subjects
11. Part 2: Composite of pharmacokinetic (PK) parameters following trametinib and palbociclib administration [ Time Frame: Cycle 1 Day 15 ]
    PK parameters will include: Cmax, tmax, AUC(0-t), CL/F, Cmin. Blood samples of approximately 2 mL for trametinib and 2 mL for palbociclib (4 mL total) will be collected for PK analysis (up to 40 subjects)

Eligibility Criteria

• Ages Eligible for Study: 18 Years and older (Adult, Older Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria:

• Inclusion Criteria for Part 1 and Part 2
• Subjects >=18 years old.
• Signed written informed consent.
• All prior anti-cancer treatment-related toxicities (except alopecia and laboratory values as listed in the protocol) must be <=grade 1 according to the Common Terminology Criteria for Adverse Events version 4 (CTCAE version 4.0) at the time of randomization.
• Able to swallow and retain oral medication and must not have any clinically significant gastrointestinal abnormalities that may alter absorption such as malabsorption syndrome or major resection of the stomach or bowels.
• Women of childbearing potential must have a negative serum pregnancy test within 7 days of first dose of study treatment and agree to use effective contraception as defined in the protocol.
• Men with a female partner of childbearing potential must have either had a prior vasectomy or agree to use effective contraception as described in the protocol.
• An Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
• Adequate baseline organ function as defined in the protocol.
• Other Inclusion criteria for Part 1
• Histologically or cytologically confirmed diagnosis of solid tumor malignancy that is not responsive to standard therapies or for which there is no approved or curative therapy.
• Subjects with cutaneous melanoma must provide either a fresh or archived tumor sample for genetic analysis including determination of or confirmation of BRAF and NRAS genetic status based on local laboratory results. To ensure prompt delivery of tumor samples, tissue shipment tracking information must be provided before administration of study treatment can be initiated.
• Other Inclusion criteria for Part 2
• Measurable disease (i.e., present with at least one measurable lesion per RECIST, version 1.1).
• Histologically or cytologically confirmed diagnosis of advanced or metastatic cutaneous melanoma that is determined to be BRAFV600 wild type and either NRAS wild type or NRAS mutation type. Note: Subjects with a melanoma of unknown primary origin may be allowed to enrol if all other types of melanoma (e.g., uveal, mucosal, or acral) can be reasonably ruled out.
• Must provide either a fresh or archived tumor sample for genetic analysis.
• Accessible tumor for biopsy and willingness to provide pre-dose tumor biopsies on Days 1 and Day 15.
• Inclusion Criteria for Part 3
• The inclusion criteria for Part 3 will be based on emerging data from Parts 1 and 2 and will be specified in an amendment.

Exclusion Criteria:

• Prior treatment with a MEK inhibitor or a CDK4/6 inhibitor.
• BRAFV600 mutation positive.
• For Part 1, subjects may have had any number of prior systemic anti-cancer treatments, but may not have received more than 2 schedules of myeloablative chemotherapy. For Parts 2 and 3, more than two prior systemic anti-cancer treatment (chemotherapy, immunotherapy, biologic therapy, vaccine therapy, or investigational treatment) for Stage IIIC (unresectable) or Stage IV (metastatic) melanoma are not permitted. Prior systemic treatment in the adjuvant setting is allowed. (Note: Ipilimumab treatment must end at least 8 weeks prior to Study Day 1 (Parts 1 and 2) or randomization (Part 3.)
• Any major surgery, extensive radiotherapy, chemotherapy with delayed toxicity, biologic therapy, or immunotherapy within 21 days prior to Study Day 1 (Parts 1 and 2) or randomization (Part 3), or daily or weekly chemotherapy without the potential for delayed toxicity within 14 days prior to Study Day 1 (Parts 1 and 2) or randomization (Part 3).
• Taken an investigational drug within 28 days or 5 half-lives (minimum 14 days), whichever is shorter, prior to Study Day 1 (Parts 1 and 2) or randomization (Part 3).
• Current use of a prohibited medication as described in the protocol.
• History of another malignancy (Part 3 only). Exception: Subjects who have been disease-free for 3 years, or subjects with a history of completely resected, non-melanoma skin cancer, or subjects with indolent second malignancies are eligible. T1a melanoma and melanoma in situ are permitted. Consult GlaxoSmithKline (GSK) Medical Monitor if unsure whether second malignancies meet requirements specified above.
• Any serious or unstable pre-existing medical conditions (aside from malignancy exceptions specified above), psychiatric disorders, or other conditions that could interfere with the subject's safety, obtaining informed consent, or compliance with study procedures.
• Known Human Immunodeficiency Virus (HIV), Hepatitis B Virus (HBV), or Hepatitis C Virus (HCV) infection (subjects with laboratory evidence of cleared HBV and HCV infection will be permitted).
• History of leptomeningeal disease or spinal cord compression secondary to metastasis.
• Brain metastasis, unless previously treated with surgery or stereotactic radiosurgery and the disease has been confirmed stable (i.e., no increase in lesion size, and stable or decreased doses of corticosteroids) for at least 6 weeks with two consecutive scans prior to Study Day 1 (Parts 1 and 2) or randomization (Part 3). (Enzyme inducing anticonvulsants are not allowed while subjects are on study treatment. Prior whole-brain radiation as adjuvant treatment is allowed.)
• A history or evidence of cardiovascular risk including any of the following: A QT interval corrected for heart rate using the Fridericia's formula (QTcF) >=480 millisecond (msec); A history or evidence of current clinically significant uncontrolled arrhythmias; Exception: Subjects with atrial fibrillation controlled for >30 days prior to Study Day 1 (Parts 1 and 2) or randomization (Part 3); History of acute coronary syndromes (including myocardial infarction and unstable angina), coronary angioplasty, or stenting within 6 months prior to Study Day 1 (Parts 1 and 2) or randomization (Part 3); A history or evidence of current >=Class II congestive heart failure as defined by the New York Heart Association (NYHA) guidelines; Treatment refractory hypertension defined as a blood pressure of systolic>140 millimeters of mercury (mmHg) and/or diastolic >90 mmHg which cannot be controlled by anti-hypertensive therapy; Patients with intra-cardiac defibrillators or permanent pacemakers; Known cardiac metastases.
• A history or current evidence/risk of Retinal Vein Occlusion (RVO) or Central Serous Retinopathy (CSR) including: History of RVO or CSR, or predisposing factors to RVO or CSR (e.g. uncontrolled glaucoma or ocular hypertension, uncontrolled systemic disease such as hypertension, diabetes mellitus, or history of hyperviscosity or hypercoagulability syndromes); or Visible retinal pathology as assessed by ophthalmic examination that is considered a risk factor for RVO or CSR such as: Evidence of new optic disc cupping; Evidence of new visual field defects; Intraocular pressure >21 mmHg as measured by tonography.
• Known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs chemically related to the study treatments, their excipients, and/or dimethyl sulfoxide (DMSO).
• History of interstitial lung disease or pneumonitis.
• Females who are nursing.

Contacts and Locations

Locations

United States, Massachusetts

GSK Investigational Site

Boston, Massachusetts, United States, 02114

United States, Tennessee

GSK Investigational Site

Nashville, Tennessee, United States, 37232

United States, Texas

GSK Investigational Site

Houston, Texas, United States, 77030-4009

Sponsors and Collaborators

GlaxoSmithKline

Pfizer

Investigators

• Study Director: GSK Clinical Trials; GlaxoSmithKline

More Information

• Responsible Party: GlaxoSmithKline
• ClinicalTrials.gov Identifier: NCT02065063
• Other Study ID Numbers: 200344
• First Posted: February 17, 2014
• Last Update Posted: June 1, 2018
• Last Verified: May 2018

Keywords provided by GlaxoSmithKline:

MEK inhibitor; PD-0332991; CDK4/6 inhibitor; palbociclib; NRAS wild type; cutaneous melanoma; GSK1120212; trametinib; NRAS mutant; BRAFV600 wild type

Additional relevant MeSH terms:

Palbociclib; Trametinib; Antineoplastic Agents; Protein Kinase Inhibitors; Enzyme Inhibitors; Molecular Mechanisms of Pharmacological Action